CMS Takes Further Steps to Ensure Medicare Beneficiaries Have Wide Access to COVID-19 Antibody Treatment

By:

The U.S. Food and Drug Administration issued an Emergency Use Authorization (EUA) for the investigational monoclonal antibody therapy, bamlanivimab and etesevimab, administered together, for the treatment of mild-to-moderate COVID-19 in adults and pediatric patients with positive COVID-19 test results who are at high risk for progressing to severe COVID-19 and/or hospitalization. Bamlanivimab and etesevimab, administered […]

Read More

COVID -19 Therapeutic Receives Emergency Use Authorization

By:

The Centers for Medicare & Medicaid Services announced that starting November 12, 2020, Medicare beneficiaries can receive coverage of monoclonal antibodies to treat coronavirus disease 2019 (COVID-19) with no cost-sharing during the public health emergency (PHE). CMS’ coverage of monoclonal antibody infusions applies to bamlanivimab, which received an emergency use authorization (EUA) from the U.S. […]

Read More

CMS Releases Interim Final Rule for COVID-19 Vaccine & Treatment, and CARES Act Provisions

By:

Late in the day on Wednesday, October 29, the Centers for Medicare & Medicaid Services (CMS) released an Interim Final Rule with Comment Period (IFC) primarily addressing COVID-19 vaccine coverage. The provisions of the IFC are effective immediately on the date of posting in the Federal Register or as otherwise specified in the rule. The […]

Read More